A stealth biotech from repeat collaborators has assembled the latest industry megaround.
New York-based NILO Therapeutics has put together a $101 million Series A, Tim …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.